Trial · NCT05788965
Semaglutide in CFRD
NCT05788965, Phase 2, Phase 3, Completed, University of Minnesota; results first posted 2026-01-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Semaglutide in CFRD. Trials, record NCT05788965. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05788965
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Semaglutide in CFRD
- NCT number
- NCT05788965
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 8 participants, actual
- Lead sponsor
- University of Minnesota
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes
- Interventions
- Semaglutide
- First posted
- 2023-03-29
- Last updated
- 2026-01-21
- Results first posted
- 2026-01-21
- Limitations and caveats
- there was no placebo control
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Weight | 12 weeks | Change in weight before and 12 weeks post treatment |
| Primary | BMI (kg/m2) | 12 weeks | Change in BMI before and 12 weeks post treatment |
| Secondary | CGM % Time in Target TIR) | 12 weeks | Change in CGM TIR before and 12 weeks post treatment. Outcome reflects the change in continuous glucose monitoring (CGM) time in range (TIR), measured at baseline and again 12 weeks after treatment initiation. TIR is defined as the percentage of time glucose values are between 70 and 180 mg/dL |
| Secondary | A1c | 12 weeks | change in the percent of HbA1c before and 12 weeks post treatment |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Weight | 12 weeks | kilograms | MEAN | |
| PRIMARY | BMI (kg/m2) | 12 weeks | kg/m2 | MEAN | |
| SECONDARY | CGM % Time in Target TIR) | 12 weeks | percentage time in target | MEAN | |
| SECONDARY | A1c | 12 weeks | change in the percent of HbA1c | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Weight | Semaglutide Treatment | -4.6 | Standard Deviation 1.9 | kilograms | |
| BMI (kg/m2) | Semaglutide Treatment | -1.8 | Standard Deviation 0.9 | kg/m2 | |
| CGM % Time in Target TIR) | Semaglutide Treatment | 7 | Standard Deviation 10.5 | percentage time in target | |
| A1c | Semaglutide Treatment | -0.3 | Standard Deviation 0.3 | change in the percent of HbA1c |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Semaglutide Treatment | 8 | |
| Overall Study | COMPLETED | Semaglutide Treatment | 8 | |
| Overall Study | NOT COMPLETED | Semaglutide Treatment | 0 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Semaglutide Treatment | 5 | 8 | 8 |
| other | Constipation | Gastrointestinal disorders | Semaglutide Treatment | 2 | 8 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Semaglutide Treatment | 1 | 8 | 2 |
| other | Heartburn | Gastrointestinal disorders | Semaglutide Treatment | 3 | 8 | 3 |
| other | Vomiting | Gastrointestinal disorders | Semaglutide Treatment | 2 | 8 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Semaglutide Treatment | 0 | 8 |
| Total, other adverse events | Semaglutide Treatment | 7 | 8 |
| Total, serious adverse events | Semaglutide Treatment | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05788965
GET https://conductscience.org/api/trials/v1/NCT05788965/registered